$-0.09
(Market cap
$34 Mln
Recently Viewed
Clear AllMarket cap
$34 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.6
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
10,139,900
CFO
$-132.26 Mln
EBITDA
$-103.24 Mln
Net Profit
$-191.15 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
| 11.8 | -3.0 | 32.4 | 52.4 | -28.3 | -49.7 | -34.1 |
|
BSE Sensex*
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
| -3.9 | -60.3 | -51.5 | -86.7 | 194.5 | -11.7 | -24.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
3.3 | 34.2 | 0.0 | -11.6 | -- | -19.7 | -- | 0.6 |
| 4.5 | 929.6 | 14.1 | -33.5 | -264.9 | -38.5 | -- | 12.1 | |
| 3.8 | 216.4 | 363.3 | -42.5 | 0.1 | -6 | -- | 0.6 | |
| 5.7 | 2,121.3 | 10,309.0 | 155.3 | 17.0 | -17 | 13.5 | 18.8 | |
| 1.4 | 512.0 | 278.4 | -326.6 | -102.3 | -52.4 | -- | 0.9 | |
| 2.9 | 1,034.6 | 193.4 | -9.5 | -8.9 | -0.9 | -- | 0.9 | |
| 0.4 | 2.4 | 54.7 | -11.3 | -16.3 | -516.3 | -- | 0.9 | |
| 3.3 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 3.3 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 1.7 | 391.4 | 946.4 | -15.8 | -1.2 | -1.4 | -- | 0.5 | |
| 3.4 | 155.9 | 84.4 | -9.2 | 0.2 | -- | -- | 20.1 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid... hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. Read more
CEO & Director
Mr. Prashant Kohli
CEO & Director
Mr. Prashant Kohli
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Acasti Pharma Inc Class A - ADR is $3.28 (NASDAQ) as of 21-Nov-2024 09:30 EDT. Acasti Pharma Inc Class A - ADR has given a return of -28.29% in the last 3 years.
Since, TTM earnings of Acasti Pharma Inc Class A - ADR is negative, P/E ratio is not available.
The P/B ratio of Acasti Pharma Inc Class A - ADR is 0.59 times as on 22-Nov-2024, a 95 discount to its peers’ median range of 12.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Acasti Pharma Inc Class A - ADR are Rs -- and Rs -- as of 23-Apr-2026.
Acasti Pharma Inc Class A - ADR has a market capitalisation of $ 34 Mln as on 22-Nov-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Acasti Pharma Inc Class A - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.